Clinical ScienceIncidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families☆,☆☆,★
Section snippets
Patients and families
Family samples were collected by research groups that are members of the IGCLC. Families were eligible for the study if they included at least 3 cases of diffuse-type gastric cancer and at least 1 affected member had tested positive for a disease-associated mutation in CDH1. Gastric cancer families in which a missense mutation in CDH1 had been identified were excluded from the analysis because the pathogenic significance of these genetic variants is not known. Twelve families meeting these
Results
A summary of the 11 families used in this analysis is shown in Table 1. The families included data on 476 individuals (241 male, 235 female). Of these there were 80 cases of gastric cancer (38 male, 42 female) with an average age of diagnosis of 40 (range, 14–85) years. Age of diagnosis tended to be slightly earlier in women (mean, 39 years) than in men (mean, 42 years). Confirmation of gastric cancers from pathology records was available for 46 patients. Of these, 44 were diffuse-type gastric
Discussion
This study confirms that carriers of a germline mutation in CDH1 have a high lifetime risk of developing gastric cancer but that the risk is less than 100%. Huntsman et al.18 reported superficial infiltrates of malignant signet-ring cells identified in all surgical samples from 5 CDH1 mutation carriers who underwent prophylactic gastrectomy. These early diffuse gastric cancers were multifocal in 3 of 5 cases, and in 1 case infiltrates of malignant signet-ring cells were present in 65 of 140
Acknowledgements
The authors thank all families, clinicians, and pathologists who contributed to this study.
References (26)
- et al.
Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation
Am J Pathol
(1999) - et al.
Altered expression of E-cadherin in breast cancer: patterns, mechanisms and clinical significance
Eur J Cancer
(2000) - et al.
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
Am J Hum Genet
(1998) - et al.
Population-based study of risk of breast cancer in carriers of BRCA2 mutation
Lancet
(1998) - et al.
E-cadherin germline mutations in familial gastric cancer
Nature
(1998) - et al.
Identification of germ-line E-cadherin mutations in gastric cancer families of European origin
Cancer Res
(1998) - et al.
Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer
Hum Mol Genet
(1999) - et al.
E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer
Hum Mutat
(1999) - et al.
Familial gastric cancer: overview and guidelines for management
J Med Genet
(1999) - et al.
Mutations of the human E-cadherin (CDH1) gene
Hum Mutat
(1998)
E-cadherin gene mutations provide clues to diffuse type gastric carcinomas
Cancer Res
E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain
Oncogene
Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility
Oncogene
Cited by (540)
Beyond genetics: Exploring the role of epigenetic alterations in breast cancer
2024, Pathology Research and PracticeHereditary gastric cancer syndromes and their association with specific histological subtypes
2023, Bulletin du CancerHereditary Diffuse Gastric Cancer
2023, GastroenterologyNanocarrier-mediated delivery for targeting stomach cancer
2023, Multifunctional Nanocomposites for Targeted Drug Delivery in Cancer Therapy
- ☆
Address requests for reprints to: Paul D. P. Pharoah, M.D., Ph.D., University of Cambridge, Strangeways Research Laboratories, Worts Causeway, Cambridge, CB18RN England. e-mail: [email protected]; fax: (44) 1223-411609.
- ☆☆
P.D.P.P. is a Cancer Research Campaign (CRC) Senior Clinical Research Fellow. P.H., M.M., and P.G. are funded by the Health Research Council of New Zealand. F.R. and E.M. are funded by the Birmingham Hospitals Endowment Research Fund and the British Digestive Foundation. Meetings of the IGCLC have been supported by grants from the Kathleen DuRoss Ford Foundation and the Bank of Siena.
- ★
Contributing centers and principal investigators in the International Gastric Cancer Linkage Consortium (the number of families contributed by each center is shown in parentheses): Carlos Caldas and Paul Pharoah, Strangeways Research Laboratories and Department of Oncology, University of Cambridge, Cambridge, England (coordinating center); Tumi Toro and Parry Guilford, Cancer Genetics Laboratory, University of Otago, Dunedin, Aetearoa, New Zealand, and Maybelle McLeod and Pauline Harawira, Kimihauora Health and Research Clinic, Mt. Maunganui, New Zealand (1); Gisela Keller and Heinz Hofler, Institute of Pathology, and H. Vogelsang, Department of Surgery, Technische Universität München, Munich, Germany (1); Frances Richards and Eamonn Maher, Section of Medical and Molecular Genetics, University of Birmingham, Birmingham, England (2); Nicola Grehan and Carlos Caldas, Department of Oncology, University of Cambridge, Cambridge, England (1); Jean-Marc Limacher, Service d'Oncologie, Hopitaux Universitaires, Strasbourg, France (1); David Huntsman, British Columbia Cancer Agency, and Patrick MacLeod, Medical Genetics, Victoria General Hospital, Victoria, British Columbia, Canada (1); Charles E. Jackson, Henry Ford Hospital, Detroit, Michigan, (1); Georgia Wiesner, Department of Genetics, University Hospitals of Cleveland/Case Western Reserve University, Cleveland, Ohio, (1); Cindy Hunter and Gail Vance, Department of Medical and Molecular Genetics, Indiana University, Indianapolis, Indiana (1); Anne E. Harty and Henry Lynch, Department of Medicine, Creighton University Medical School, Omaha, Nebraska (1); Noralane M. Lindor and Larry J. Burgart, Mayo Clinic, Rochester, Minnesota (1).